New York, NY -- (SBWIRE) -- 12/16/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Atmel Corporation (NASDAQ:ATML), GT Advanced Technologies Inc (NASDAQ:GTAT), Merrimack Pharmaceuticals Inc (NASDAQ:MACK), McDermott International (NYSE:MDR)
Atmel Corporation (NASDAQ:ATML) showed a volume of 3.04 million shares by the end of last trade whereas the average volume of the stock remained 5.27 million shares. The stock opened the session at $7.37 but then moved to $7.21. At that price, the stock showed a negative performance of -1.90%. Atmel Corporation (Atmel) is engaged in designing, developing and supplying of microcontrollers. Atmel offers a portfolio of touch products, which integrate its microcontrollers with touch-focused intellectual property (IP). Its semiconductors also enable applications in many other fields, such as smart-metering for utility monitoring and billing, buttons, sliders and wheels found on the touch panels of appliances, various aerospace,
Will ATML Get Buyers Even After The Recent Rally? Find Out Here
GT Advanced Technologies Inc (NASDAQ:GTAT) opened the session at $8.08 and closed the session at $8.02. The stock showed a negative performance of -0.37% in previous trading session. Traded with volume of 2.98 million shares in the prior session and the average volume of the stock remained 7.21 million shares. GT Advanced Technologies Inc. is diversified technology company with crystal growth equipment and solutions for the global solar, light emitting diode (LED) and electronics industries. The Company operates in three segments: its polysilicon business, its photovoltaic (PV), business and its sapphire business.
Has GTAT Found The Bottom And Ready To Gain Momentum? Find Out Here
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) opened the session at $4.70 and closed the session at $4.54. Traded with volume of 2.96 million shares in the prior session and the average volume of the stock remained 2.69million shares. Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. The Company’s product candidates include MM-398, MM-121, MM-111, MM-302 and MM-151.
Is MACK a Solid Investment at These Levels? Read This Report For Details
McDermott International (NYSE:MDR) the stock decreased -0.25% and finished the session at $8.03. Traded with volume of 2.89 million shares in the prior session and the average volume of the stock remained 5.61 million shares. The beta of the stock remained 1.48. McDermott International, Inc. (MII) is a engineering, procurement, construction and installation (EPCI) company. The Company is focused on designing and executing complex offshore oil and gas projects worldwide. The Company provides fully integrated EPCI services; it delivers fixed and floating production facilities, pipeline installations and subsea systems from concept to commissioning.
Will MDR Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)